JP2020517261A5 - - Google Patents

Download PDF

Info

Publication number
JP2020517261A5
JP2020517261A5 JP2019556929A JP2019556929A JP2020517261A5 JP 2020517261 A5 JP2020517261 A5 JP 2020517261A5 JP 2019556929 A JP2019556929 A JP 2019556929A JP 2019556929 A JP2019556929 A JP 2019556929A JP 2020517261 A5 JP2020517261 A5 JP 2020517261A5
Authority
JP
Japan
Prior art keywords
cancer
ifn
cells
mir
cytokine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019556929A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020517261A (ja
JP7252135B2 (ja
Filing date
Publication date
Priority claimed from GBGB1706410.6A external-priority patent/GB201706410D0/en
Priority claimed from GBGB1801511.5A external-priority patent/GB201801511D0/en
Application filed filed Critical
Priority claimed from PCT/EP2018/060238 external-priority patent/WO2018193119A1/en
Publication of JP2020517261A publication Critical patent/JP2020517261A/ja
Publication of JP2020517261A5 publication Critical patent/JP2020517261A5/ja
Priority to JP2023046113A priority Critical patent/JP2023078376A/ja
Application granted granted Critical
Publication of JP7252135B2 publication Critical patent/JP7252135B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019556929A 2017-04-21 2018-04-20 遺伝子療法 Active JP7252135B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023046113A JP2023078376A (ja) 2017-04-21 2023-03-23 遺伝子療法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1706410.6 2017-04-21
GBGB1706410.6A GB201706410D0 (en) 2017-04-21 2017-04-21 Type 1 interferon gene therapy
GBGB1801511.5A GB201801511D0 (en) 2018-01-30 2018-01-30 Gene therapy
GB1801511.5 2018-01-30
PCT/EP2018/060238 WO2018193119A1 (en) 2017-04-21 2018-04-20 Gene therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023046113A Division JP2023078376A (ja) 2017-04-21 2023-03-23 遺伝子療法

Publications (3)

Publication Number Publication Date
JP2020517261A JP2020517261A (ja) 2020-06-18
JP2020517261A5 true JP2020517261A5 (enExample) 2021-06-10
JP7252135B2 JP7252135B2 (ja) 2023-04-04

Family

ID=62165525

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019556929A Active JP7252135B2 (ja) 2017-04-21 2018-04-20 遺伝子療法
JP2023046113A Pending JP2023078376A (ja) 2017-04-21 2023-03-23 遺伝子療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023046113A Pending JP2023078376A (ja) 2017-04-21 2023-03-23 遺伝子療法

Country Status (23)

Country Link
US (1) US20200078408A1 (enExample)
EP (2) EP4491233A3 (enExample)
JP (2) JP7252135B2 (enExample)
KR (1) KR102733541B1 (enExample)
CN (1) CN110785488A (enExample)
AU (1) AU2018253959B2 (enExample)
BR (1) BR112019021953A2 (enExample)
CA (1) CA3060145A1 (enExample)
DK (1) DK3612624T3 (enExample)
ES (1) ES2995785T3 (enExample)
FI (1) FI3612624T3 (enExample)
HR (1) HRP20241603T1 (enExample)
HU (1) HUE069690T2 (enExample)
IL (2) IL270028B2 (enExample)
LT (1) LT3612624T (enExample)
MX (2) MX2024012024A (enExample)
PL (1) PL3612624T3 (enExample)
PT (1) PT3612624T (enExample)
RS (1) RS66264B1 (enExample)
SG (1) SG11201909814WA (enExample)
SI (1) SI3612624T1 (enExample)
SM (1) SMT202400506T1 (enExample)
WO (1) WO2018193119A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020163868A1 (en) * 2019-02-09 2020-08-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Genetically modified hematopoietic stem and progenitor cells (hspcs) and mesenchymal cells as a platform to reduce or prevent metastasis, treat autoimmune and inflammatory disorders, and rebalance the immune milieu and dysregulated niches
AU2020225917A1 (en) * 2019-02-22 2021-08-26 Oncolytics Biotech Inc. T cell repertoire dynamics and oncolytic viral therapy
WO2020191358A1 (en) * 2019-03-20 2020-09-24 Bluebird Bio, Inc. Adoptive cell therapy
CN112280829B (zh) * 2020-04-07 2023-12-26 南方科技大学 一种试剂盒、样本标记方法、单细胞测序方法
KR20230010231A (ko) * 2020-05-11 2023-01-18 아빈투스 바이오, 인코포레이티드 생체내 형질도입을 위한 벡터 및 방법
GB202007169D0 (en) * 2020-05-14 2020-07-01 Ospedale San Raffaele Srl Epidermal growth factor receptor
EP4161536A4 (en) * 2020-06-04 2024-08-14 Carisma Therapeutics Inc. Novel constructs for chimeric antigen receptors
CN114426953A (zh) * 2020-10-29 2022-05-03 未来智人再生医学研究院(广州)有限公司 一种表达il-12的多能干细胞衍生物及应用
CN114460304A (zh) * 2020-11-03 2022-05-10 广州辑因医疗科技有限公司 细胞制剂、蛋白在表征造血干细胞中的用途及判定造血干细胞的方法
CN114807155A (zh) * 2021-01-18 2022-07-29 华东师范大学 用于基因编辑的组合物及其应用
WO2024068617A1 (en) * 2022-09-26 2024-04-04 Institut Curie Myeloid cells expressing il-2 and uses thereof for quick anticancer therapy
CN120603934A (zh) * 2023-02-08 2025-09-05 国立大学法人九州大学 能够在肿瘤组织内分化成m2巨噬细胞且分化成m2巨噬细胞时表达炎性细胞因子的细胞和含有该细胞的组合物
WO2024194223A2 (en) * 2023-03-17 2024-09-26 Ospedale San Raffaele S.R.L. Gene therapy
WO2025217427A1 (en) * 2024-04-11 2025-10-16 Genenta Science S.P.A. Combination immunotherapy of solid cancers

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9803351D0 (en) * 1998-02-17 1998-04-15 Oxford Biomedica Ltd Anti-viral vectors
GB0009760D0 (en) 2000-04-19 2000-06-07 Oxford Biomedica Ltd Method
PT2856876T (pt) * 2007-03-30 2018-03-28 Memorial Sloan Kettering Cancer Center Expressão constitutiva de ligantes co-estimulatórios em linfócitos t adotivamente transferidos
AU2010243276B2 (en) * 2009-04-30 2016-09-15 Fondazione Telethon Ets Gene vector
HK1217215A1 (zh) * 2013-01-17 2016-12-30 Modernatx, Inc. 用於改变细胞表型的信号传感器多核苷酸
EP3347375B1 (en) * 2015-09-10 2020-12-23 The United States of America, as represented by The Secretary, Department of Health and Human Services Anti-cd276 chimeric antigen receptors
JP2018536436A (ja) * 2015-12-04 2018-12-13 ノバルティス アーゲー 免疫腫瘍学のための組成物および方法

Similar Documents

Publication Publication Date Title
JP2020517261A5 (enExample)
US20220204628A1 (en) Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
Helmy et al. Cancer immunotherapy: accomplishments to date and future promise
Marin-Acevedo et al. Cancer immunotherapy beyond immune checkpoint inhibitors
Yousefi et al. Immunotherapy of cancers comes of age
Maus et al. Making better chimeric antigen receptors for adoptive T-cell therapy
Dotti et al. Design and development of therapies using chimeric antigen receptor‐expressing T cells
Baxevanis et al. Cancer immunotherapy
Kiesgen et al. Chimeric antigen receptor (CAR) T-cell therapy for thoracic malignancies
Houot et al. T-cell–based immunotherapy: adoptive cell transfer and checkpoint inhibition
AU2014225788B2 (en) Engager cells for immunotherapy
Lin et al. Cellular immunotherapy for malignant gliomas
HRP20241603T1 (hr) Genska terapija
US11229668B2 (en) Maximizing T-cell memory and compositions and methods therefor
AU2019387566A1 (en) Chimeric antigen receptor factories and methods of use thereof
US20230398216A1 (en) Chimeric activation receptors
Hinrichs Molecular pathways: breaking the epithelial cancer barrier for chimeric antigen receptor and T-cell receptor gene therapy
Shirjang et al. Promising immunotherapy: Highlighting cytokine‐induced killer cells
Xu et al. Chimeric antigen receptor T-cell therapy: challenges and opportunities in lung cancer
Azizi et al. T-cell receptor and chimeric antigen receptor in solid cancers: current landscape, preclinical data and insight into future developments
Knight et al. Beyond immune checkpoint inhibitors: emerging targets in melanoma therapy
Nardo et al. Associação Brasileira de Hematologia, Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. Review article: Cell therapy in solid tumors
Yu et al. CAR NK cell therapy for solid tumors: Potential and challenges
Kucharczyk et al. Adoptive T-Cell Therapy in Sarcomas
US20240148867A1 (en) Methods of treating cancer with a combination of adoptive cell therapy and a targeted immunocytokine